Opportunity Information: Apply for RFA CA 12 504
Apply for RFA CA 12 504
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "NCI National Clinical Trials Network Canadian Collaborating Clinical Trials Network (Limited Competition U10)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Jul 23, 2012 and posted on Jul 23, 2012.
- Applicants must submit their applications by Jan 15, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (Limited Competition U10)" (Funding Opportunity Number RFA-CA-12-504) is a National Institutes of Health (NIH), National Cancer Institute (NCI) cooperative agreement designed to support the creation of a Canadian Collaborating Clinical Trials Network that can formally participate in and strengthen the NCI National Clinical Trials Network (NCTN). The central purpose is to build and maintain an organized Canadian network that can work in close coordination with NCI-sponsored U.S. trial infrastructure to help design and conduct modern cancer clinical trials, including both therapeutic studies and advanced imaging trials. The emphasis is on large, definitive, multi-institutional trials that evaluate new cancer therapies and related clinical approaches, and it explicitly includes both adult and pediatric patient populations.
This FOA sits within the broader NCTN structure, which is described as having six coordinated components, each supported through its own separate funding announcement. Those components include Network Group Operations Centers, Network Group Statistics and Data Management Centers, Network Group Integrated Translational Science Centers, Lead Academic Participating Site Centers, Network Radiotherapy and Imaging Core Services Centers, and the Canadian Collaborating Clinical Trials Network (the focus of this particular FOA). In practical terms, the Canadian component is meant to serve as an organized partner that enables Canadian institutions to contribute patients, clinical sites, and expertise to NCTN-led research in a consistent, high-quality, and operationally aligned way, rather than participating only on an ad hoc basis. Because it is a cooperative agreement (U10), the award mechanism signals that the funded network would be expected to work closely with NCI staff and the broader NCTN governance and operational processes, with substantial federal involvement typical of cooperative agreements.
From an eligibility standpoint, the announcement is broad and allows applications from a wide range of organizational types, including public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), and for-profit organizations other than small businesses. The opportunity also lists several categories of institutions that are explicitly included (such as Historically Black Colleges and Universities, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and regional organizations), reflecting NIH-wide eligibility language. Importantly for this particular Canadian network objective, non-U.S. entities (foreign institutions) are eligible to apply, and foreign components are allowed as defined under NIH policy, although non-domestic components of U.S. organizations are stated as not eligible to apply as components. The FOA does not require cost sharing or matching funds.
In terms of funding and timing, the estimated total funding level is listed as $3,000,000. The FOA was posted and created on July 23, 2012, with an original and current closing date of January 15, 2013, and an archive date of February 15, 2013, indicating it is no longer open for new applications and is preserved for historical reference. The activity areas referenced align with cancer detection/diagnosis research and cancer treatment research (CFDA 93.394 and 93.395), which fits the stated focus on treatment trials and advanced imaging studies.
Overall, this opportunity is best understood as NCI support for a formal Canadian partner network that can plug into the NCTN ecosystem and help deliver large-scale, high-impact oncology trials across borders. By funding a Canadian collaborating network under a U10 cooperative agreement, NCI aimed to ensure Canadian participation is operationally integrated with NCTN trial development and conduct, supporting the broader NCTN mission of running state-of-the-art, practice-informing clinical trials efficiently across many institutions. For full details, the archived announcement was hosted on the NIH Grants Guide website under the link provided in the source material (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-504.html).
FAQs: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (Limited Competition U10) (RFA-CA-12-504)
What is this funding opportunity?
This is an NIH National Cancer Institute (NCI) cooperative agreement funding opportunity titled "NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (Limited Competition U10)." Its Funding Opportunity Number is RFA-CA-12-504.
What is the main purpose of the award?
The main purpose is to create and support an organized Canadian Collaborating Clinical Trials Network that can formally participate in and strengthen the NCI National Clinical Trials Network (NCTN). The goal is to enable consistent, high-quality Canadian participation in NCTN-led clinical trials rather than ad hoc involvement.
What kind of funding mechanism is used?
The award uses a U10 cooperative agreement mechanism. This indicates substantial federal involvement, meaning the funded network would be expected to work closely with NCI staff and align with NCTN governance and operational processes.
How does the Canadian Collaborating Clinical Trials Network fit into the broader NCTN structure?
This FOA is one component within the broader NCTN, which is described as having six coordinated components supported by separate funding announcements. The Canadian Collaborating Clinical Trials Network is specifically intended to serve as a formal Canadian partner that can plug into the NCTN ecosystem.
What are the six coordinated components of the NCTN mentioned in the announcement?
The six components described are: Network Group Operations Centers; Network Group Statistics and Data Management Centers; Network Group Integrated Translational Science Centers; Lead Academic Participating Site Centers; Network Radiotherapy and Imaging Core Services Centers; and the Canadian Collaborating Clinical Trials Network (the focus of this FOA).
What types of clinical trials are supported or emphasized?
The emphasis is on large, definitive, multi-institutional cancer clinical trials designed to evaluate new cancer therapies and related clinical approaches. The scope explicitly includes both therapeutic studies and advanced imaging trials.
Does the opportunity include both adult and pediatric cancer research?
Yes. The opportunity explicitly includes both adult and pediatric patient populations.
What is meant by "advanced imaging trials" in this context?
The FOA specifically calls out advanced imaging trials as part of the modern cancer clinical trial portfolio the Canadian network would help design and conduct in coordination with NCTN infrastructure.
What is the practical role of the Canadian network within NCTN-led research?
The Canadian component is intended to provide an organized partner structure so Canadian institutions can contribute patients, clinical sites, and expertise to NCTN-led research in an operationally aligned way.
Who is eligible to apply?
The eligibility language is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (with and without 501(c)(3) status), and for-profit organizations other than small businesses. Several categories of institutions are also explicitly listed as included, consistent with NIH-wide eligibility language.
Are non-U.S. (foreign) organizations eligible?
Yes. Non-U.S. entities (foreign institutions) are eligible to apply, and foreign components are allowed as defined under NIH policy.
Are non-domestic components of U.S. organizations eligible to apply as components?
No. The FOA states that non-domestic components of U.S. organizations are not eligible to apply as components.
Is cost sharing or matching required?
No. The FOA does not require cost sharing or matching funds.
What is the estimated total funding level?
The estimated total funding level listed in the announcement is $3,000,000.
When was the funding opportunity posted and when did it close?
The FOA was posted and created on July 23, 2012. The original and current closing date was January 15, 2013.
Is this opportunity currently open for applications?
No. The FOA has an archive date of February 15, 2013, indicating it is no longer open for new applications and is maintained for historical reference.
What NIH/NCI research areas or program areas does this FOA align with?
The activity areas referenced align with cancer detection/diagnosis research and cancer treatment research.
What CFDA numbers are associated with this opportunity?
The announcement references CFDA 93.394 and 93.395.
Where can someone find the archived full announcement?
The archived announcement is available on the NIH Grants Guide website at: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-504.html
What does "limited competition" mean in the title?
The title includes the phrase "Limited Competition," indicating the funding opportunity was structured as a limited competition. The provided summary does not specify additional details about how the limitation was implemented.
What does this FOA aim to improve compared to ad hoc participation?
It aims to make Canadian participation in NCTN research consistent, high-quality, and operationally integrated with NCTN trial development and conduct, instead of relying on ad hoc site-by-site arrangements.
What kinds of contributions from Canadian institutions are envisioned?
The FOA describes contributions such as providing patients, clinical sites, and oncology expertise, coordinated through an organized Canadian network that aligns with NCTN processes.
Browse more opportunities from the same category: Education Health
Next opportunity: NCI National Clinical Trials Network Network Group Operations Centers (U10)
Previous opportunity: NCI National Clinical Trials Network Network Radiotherapy and Imaging Core Services Centers (U24)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 12 504
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 12 504) also looked into and applied for these:
| Funding Opportunity |
|---|
| NCI National Clinical Trials Network Network Group Operations Centers (U10) Apply for RFA CA 12 010 Funding Number: RFA CA 12 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Statistics and Data Management Centers (U10) Apply for RFA CA 12 011 Funding Number: RFA CA 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Integrated Translational Science Centers (U10) Apply for RFA CA 12 012 Funding Number: RFA CA 12 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Lead Academic Participating Sites (U10) Apply for RFA CA 12 013 Funding Number: RFA CA 12 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 12 251 Funding Number: PAR 12 251 Agency: National Institutes of Health Category: Education Health Funding Amount: $75,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 12 023 Funding Number: RFA CA 12 023 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R01) Apply for RFA DA 13 010 Funding Number: RFA DA 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R21) Apply for RFA DA 13 011 Funding Number: RFA DA 13 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Examination of Survivorship Care Planning Efficacy and Impact R21 Apply for PA 12 274 Funding Number: PA 12 274 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Examination of Survivorship Care Planning Efficacy and Impact R01 Apply for PA 12 275 Funding Number: PA 12 275 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| FY 2013 American Schools and Hospitals Abroad Program Apply for DRAFT APS ASHA 12 000001 Funding Number: DRAFT APS ASHA 12 000001 Agency: Agency for International Development Category: Education Health Funding Amount: $2,000,000 |
| HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21) Apply for PA 12 280 Funding Number: PA 12 280 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01) Apply for PA 12 281 Funding Number: PA 12 281 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS Science Track Award for Research Transition (R03) Apply for PA 12 282 Funding Number: PA 12 282 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Revisions for Early Stage Development of Informatics Technology (R01) Apply for PAR 12 286 Funding Number: PAR 12 286 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Advanced Development of Informatics Technology (U24) Apply for PAR 12 287 Funding Number: PAR 12 287 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Early Stage Development of Informatics Technology (U01) Apply for PAR 12 288 Funding Number: PAR 12 288 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Revisions for Early Stage Development of Informatics Technology (U01) Apply for PAR 12 289 Funding Number: PAR 12 289 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions for Early Stage Development of Informatics Technology (P01) Apply for PAR 12 290 Funding Number: PAR 12 290 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Research Answers to NCIs Provocative Questions Group A (R01) Apply for RFA CA 12 015 Funding Number: RFA CA 12 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 12 504", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.